Kornimate/medical-research-clean huggingface dataset:
intraoperative fluorescence of ganglogliomas and neuroepithelial dysembryoplastic tumors

Conditions: Surgical Procedure, Unspecified

Summary: one of the key issues of tumour brain surgeries is to clearly define the borders of the tumor. the investigators proposed to evaluate the feasibility of intraoperative fluorescein guidance. patients will be identified from the list of patients operated on under fluorescence to collect clinical datas. surgical videos will be analyzed to assess the presence of intraoperative fluorescence and its subjectively judged intensity. mri data will be extracted from the radiological reports to assess quality extraction. no additional data will be produced

gangliogliomas typically present as a slow-growing, cystic mass taking contrast, while dysembryoplastic neuro-epithelial tumors commonly show microcystic patterns, inconstant contrast-enhancement and are preferentially located on the internal face of the temporal lobe. the cornerstone of the treatment of these two entities remains surgery, as it provides good oncological outcomes and control of seizures. surgical resection keeps a major role for these tumors. thus, one of the key issues is to clearly define the borders of the tumor during surgery, a point of considerable importance for these curable lesions. then, the investigators proposed to evaluate the feasibility of intraoperative fluorescein guidance, a technique based on the staining of blood-brain barrier breakdown areas with fluorescein. patients will be identified from the list of patients operated on under fluorescence maintained by the department since the acquisition of the technique. clinical datas will be collected and surgical videos will be analyzed to assess the presence of intraoperative fluorescence and its subjectively judged intensity (absent, weak, medium, strong). mri data (quality of excision: total, subtotal or partial according to usual criteria) will be extracted from the radiological reports. no additional data will be produced

Eligibility criteria:
inclusion criteria: * over 18 years old patient * fluoroguided removal of a histologically proven ganglioglioma or dysembryoplastic neuroepithelial tumors between 2015-2018 * surgical video available exclusion criteria: * absence of surgical video * adults who are subject to legal protection (protection of justice, guardianship, guardianship) * patient objecting to the use of their data

Keywords: fluorescein gangliogliomas glioneuronal dysembryoplastic neuroepithelial tumor
s-equol in alzheimer's disease 2 trial

Conditions: Alzheimer Disease

Summary: by doing this study researchers hope to learn if s-equol, a compound that acts like estrogen in the body, causes an increase in mitochondrial activity. researchers also hope to determine the safety and tolerability of a therapeutic dose of s-equol and whether or not it influences cognition.

enrolled participants with a diagnosis of alzheimer's disease (ad) will be randomized to receive either s-equol or placebo first, and then cross over to receive the opposite intervention. the study, therefore, consists of two treatment periods with randomly assigned treatment order. specifically, subjects are randomized to either: (1) s-equol for one month, then placebo for one month; or (2) placebo for one month, then s-equol for one month.

Eligibility criteria:
inclusion criteria: * have a diagnosis of alzheimer's disease (ad) * have a study partner who has a close relationship with the participant and will attend study visits with the participant * do not possess an alkylphenol ethoxylates 4 (apoe4) variant of the apoe gene * speak english as their primary language * have not had any medication changes within the past 30 days exclusion criteria: * reside in a nursing home or dementia special care unit * have a potentially confounding, serious medical risk such as insulin-requiring diabetes, any history of cancer that required a chemotherapy or radiation therapy intervention within the past 5 years, or a recent cardiac event * have any clinically significant abnormal safety laboratory values at the sead2 screening visit * have any clinically significant abnormal findings on vital signs measurements, or on physical or neurological examination at the sead2 screening visit * use any type of systemic estrogen or testosterone replacement therapy * has participated in another clinical trial or received any investigational drug or investigational therapy within 30 days before the screening visit
acute responses to a potentiation warm-up protocol in female football players.

Conditions: Athletic Performance

Summary: this study aims to determine if the performance of female football players is affected after exposure to a potentiation protocol. it is hypothesized that performance in the selected physical tests will improve significantly and meaningfully after performing the chosen potentiation protocol compared to the control group's warm-up.


Eligibility criteria:
inclusion criteria: * players from any playing position (except goalkeepers) able to train without limitations. exclusion criteria: * players with any existing medical conditions that could compromise participation.

Keywords: performance enhancement warm-up sprint change of direction women's football
effects on respiratory patterns and patient-ventilator synchrony using pressure support ventilation

Conditions: Acute Respiratory Distress Syndrome; COPD; Post Operative

Summary: pressure support ventilation use expiratory triggering sensitivity(esense) to transfer inspiration to expiration,the value of esense is fixed.that may lead to asynchrony between humans and ventilators,making people uncomfortable and prolonging weaning time.some ventilators have auto cycle function based on curves of pressure on respiratory patterns,it will make the transforming more synchrony with humans.our prospective observational study will prove the superiority of the auto cycle function.

from august 31st 2016 to august 31st 2017, all ards 、copd and postoperative patients admitted to the icus will be enrolled. the demographic characteristics, diagnosis, formerly medical history, ventilator indications, ventilator data, other respiratory treatments, weaning outcome and 28 day mortality will be recorded

Eligibility criteria:
inclusion criteria: ards,copd and postoperative patient exclusion criteria: variety of reasons can not be placed next to the bed by the nasal eadi catheter

Keywords: synchrony pressure support ventilation
association of dysbiosis and immune response in bronchiolitis in under 12 months -old infants

Conditions: Bronchiolitis

Summary: acute bronchiolitis is a common disease in children under the age of two, caused mainly by the respiratory syncytial virus (rsv). furthermore, given the same medical history, it is still very difficult to predict the course and severity of the infection at the onset of symptoms, some studies have highlighted the importance of the microbiota (intestinal, oral or nasopharyngeal) and of the immune response to rsv in children, we will include 80 children under 2 years old with hospitalized bronchiolitis and non-hospitalized bronchiolitis. oral, nasal and stool samples will be taken to study the various microbiota in search of dysbiosis. a capillary blood sample will be taken for immune studies.


Eligibility criteria:
inclusion criteria: * infants \<12 months * with bronchiolitis during rsv epidemic season * no chronic illness * no bronchiolitis medical history * signed consent from parents or legal guardians exclusion criteria: * chronic respiratory illness * medical history of bronchiolitis or newborn asthma * treatment with immunosuppressants * patient with no social security affiliation

Keywords: newborns dysbiosis respiratory syncytial virus (rsv)
psychological interventions to prevent late effects in breast cancer

Conditions: Pain, Postoperative; Fatigue; Breast Cancer

Summary: the study aims to investigate whether a combined pre-operative medical hypnosis plus a post-operative internet-based acceptance and commitment intervention are more effective in preventing post-surgical pain and fatigue following breast cancer surgery compared with pre-operative mindfulness plus treatment as usual.

the trial will include 200 patients undergoing breast cancer surgery at oslo university hospital. the patients will be randomized into two groups. one group will receive a 20 minute pre-surgical hypnosis session delivered by an experienced clinical psychologist plus a post-surgical internet-based acceptance and commitment intervention. the control group will receive a 20 minute pre-surgical mindfulness session delivered through an audio recording plus treatment as usual. the primary outcomes of the study are quantitative measures of post-surgical pain and fatigue. in addition, relationships between biomarkers of stress and subacute post-surgical pain and fatigue will be analyzed using using blood- and hair samples. the study uses a longitudinal design with baseline measures obtained pre-surgery and follow up measures obtained 3 and 12 months post-surgery.

Eligibility criteria:
inclusion criteria: * women diagnosed with breast cancer and scheduled for surgery * be able to provide informed consent exclusion criteria: * insufficient norwegian speaking or writing skills to participate in the interventions and fill out questionnaires * cognitive and psychiatric impairment * other serious malignancies

Keywords: breast cancer post-surgical pain fatigue hypnosis acceptance and commitment therapy
oxygen therapy in diabetic kidney disease

Conditions: Diabetic Kidney Disease

Summary: diabetic kidney disease (dkd) is the most significant cause of end-stage kidney disease (eskd). albuminuria, evolving from microalbuminuria to nephrotic-range proteinuria, is a clinical hallmark of diabetic nephropathy (dn). it develops in about a third of diabetic patients and is considered an independent risk factor in the progression of dn and for all-cause mortality.

according to the international diabetes federation's report, over 530 million people worldwide have diabetes . about one-third of diabetic patients develop diabetic nephropathy (dn) after the incubation period, which may last several years. diabetic kidney disease (dkd) is the most significant cause of end-stage kidney disease (eskd). albuminuria, evolving from microalbuminuria to nephrotic-range proteinuria, is a clinical hallmark of diabetic nephropathy (dn). it develops in about a third of diabetic patients and is considered an independent risk factor in the progression of dn and for all-cause mortality. the management of diabetes includes lifestyle modifications, pharmacological interventions, and emerging therapies such as hyperbaric oxygen therapy (hbot). it involves exposing patients to high levels of oxygen in a pressurized chamber, leading to various physiological effects . hbot increases the level of oxygen in tissues by complete saturation of haemoglobin and increasing the partial pressure of oxygen dissolved in plasma. this enables oxygen to diffuse into tissues compromised by acute inflammation and microvascular disease and dysfunction.

Eligibility criteria:
inclusion criteria: - diabetic male and female patients aged \> 18 yrs with diabetic kidney disease (egfr 30-90 ml/min/1.73m² and proteinuria \>300 mg/day) exclusion criteria: * age \< 18 yrs * cardiovascular disease (thorough assessment of the patient's medical history (symptoms suggestive of cvd (e.g., chest pain, shortness of breath, fatigue), family history of cvd and risk factors (e.g., hypertension, hyperlipidemia, smoking). physical examination including blood pressure measurement, auscultation of heart sounds and assessment of peripheral pulses. additional diagnostic tests: stress test (stress ecg and stress echocardiography): evaluate cardiac function under stress, which can help detect coronary artery disease or other cvd. * chronic lung disease (copd, pulmonary fibrosis ... * other chronic disease affecting kidney function (lupus nephritis). * pregnancy or lactation.
genetic influence on susceptibility to type 1 diabetes mellitus

Conditions: Diabetes Mellitus; Healthy

Summary: type 1 diabetes mellitus is an autoimmune disease in which the body's immune cells attack the insulin-producing cells of the pancreas. several environmental and genetic factors may predispose individuals to developing this disease, including changes in a gene called cd152. this study will examine how this gene may influence the development of insulin-dependent diabetes. patients with type 1 diabetes mellitus enrolled in clinical trials at the national institutes of health and at the university of florida and healthy normal volunteers may participate in this study. participants will have up to three blood samples drawn over a period of less than 1 year. the first sample (about 20 milliliters, or 4 teaspoons), will be examined for changes in the structure of the cd152 gene. if the cd152 structure is different from that normally seen in the general population, a second sample (about 90 ml, or 6 tablespoons of blood) will be drawn. this sample will be used to study the function of specialized immune system cells (t cells), including their growth and survival, chemicals they produce when stimulated, and other factors. if these cells function differently from what is generally seen in the population, a third sample (90 ml) will be drawn for more detailed studies. this investigation may help explain what makes certain individuals susceptible to type 1 diabetes mellitus and may contribute to the development of improved treatments for the disease.

genetic variations in cd152 have been reported to confer susceptibility to the development of type-1-diabetes mellitus (t1dm). in this protocol we will draw blood samples from patients and normal control volunteers in order to analyze for the presence of cd152 genetic variations and to determine whether those variations are associated with measurable abnormalities in t cell function. subjects with t1dm and homozygous cd152 gene polymorphisms, patients with t1dm but without cd152 polymorphisms, and control subjects with or without cd152 polymorphisms will be studied to determine whether the cd152 polymorphisms have measurable effects on t cell function and signaling. we will assess t cell function by measuring: proliferation, viability, apoptosis, cytokine production and t cell signal transduction. the identification and characterization of genes that are linked to t1dm may provide an explanation into the mechanisms by which individuals are predisposed to t1dm.

Eligibility criteria:
patients must have a willingness and legal ability to give consent, or permission. candidates with t1dm or healthy volunteers will be eligible. patients must be equal to or greater than 18 years of age. patients must not have an active malignancy. patients with a hemoglobin count of less than 9.0 mg/dl will be excluded. patients may be on erythropoietin therapy, but will not be placed on therapy solely to facilitate research sample acquisition. patients must not have a known immunodeficiency syndrome.

Keywords: diabetes gene
empagliflozin in heart failure patients with reduced ejection fraction

Conditions: Heart Failure With Reduced Ejection Fraction

Summary: to assess the effect of empagliflozin on cardiac biomarkers, cardiac function at rest and during stress, cardiac hemodynamics, renal function, metabolism, daily activity level and health-related quality of life in stable, symptomatic heart failure patients with reduced left ventricular ejection fraction. the primary hypothesis is that 3 months' treatment with empagliflozin 10 mg a day will reduce the plasma concentrations of n-terminal pro-brain natriuretic peptide (nt-probnp).


Eligibility criteria:
inclusion criteria: * optimal heart failure therapy in accordance with european and national guidelines * lvef ≤ 0.40 * egfr \> 30 ml/min/1.73 m2 * bmi \< 45 kg/m2 * nyha class i-iii * age \> 18 years * if t2d - optimal treatment in accordance with european and national guidelines * if t2d - stable doses of antiglycemic treatment for 30 days * if t2d - hba1c 6.5-10% exclusion criteria: * crt-d/-p implanted \< 90 days * uncorrected severe valvular disease * non-compliance * use of metalozone * nyha iv * age \> 85 years * dementia * admission for hf \< 30 days * admission for hypoglycemia \< 12 month * known sustained vt * symptomatic hypotension and systolic bp \< 95 mmhg * unable to perform an exercise test * immobilization * pregnancy * participation in other medical trials * previous intolerance of empagliflozin or excipients
remimazolam in the extraction of impacted wisdom teeth

Conditions: Dental Anxiety; Sedation Complication; Anterograde Amnesia

Summary: benzodiazepines, represented by midazolam, are often used for sedation in outpatient surgery in dentistry. however, midazolam has the problems of slow consciousness recovery and long recovery time, which brings trouble to the patients. remimazolam is a new type of ultra short acting sedative anesthetic. compared with other similar products, remimazolam has faster effect, rapid metabolism and has no accumulation, which may mean that compared with midazolam, remimazolam has a better clinical application prospect in dental outpatient surgery.

the patients were randomly divided into midazolam group and remimazolam group. the onset time of drugs, postoperative recovery time, vital signs, anterograde amnesia and other complications were observed.

Eligibility criteria:
inclusion criteria: consenting patients will be eligible if they: 1. have mandibular impacted wisdom teeth that need to be extracted; 2. have a body mass index (bmi) between 18.5 and 30 kg/m2; 3. are aged between 18 and 60 years; 4. have american society of anesthesiology (asa) classification grade of i-ii; 5. have modified dental anxiety scale (mdas) score \> 15; and 6. volunteered to accept intravenous sedation. exclusion criteria: patients will be ineligible if they: 1. are pregnant; 2. experience respiratory infections, asthma attack or persistent state; 3. have contraindications to anaesthesia or a previous abnormal surgical anaesthesia recovery history; 4. have severe cardiopulmonary insufficiency; 5. have preoperative blood pressure \> 160/100 mmhg or diastolic blood pressure \> 100 mmhg, or blood pressure \< 90/60 mmhg; 6. have a neuromuscular or mental disorder that renders them unable to communicate or cooperate effectively or sign informed consent; 7. are suspected of abusing narcotic analgesics or sedatives; 8. have a known allergy or contraindication to benzodiazepines; or 9. have participated in other drug trials within 6 months.
interplay of mirna-146a and mirna-126 in chronic periodontitis patients with coronary artery disease

Conditions: Chronic Periodontitis; Coronary Artery Disease; miRNA

Summary: the role of micro-rnas in chronic periodontitis associated with cad is still in an incipient stage needs to be explored further. the investigators attempt to quantify and compare the levels of micro-rna 146a and micro-rna 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease.

the role of micro-rnas in chronic periodontitis associated with cad is still in an incipient stage needs to be explored further. the investigators attempt to quantify and compare the levels of micro-rna 146a and micro-rna 126 in subgingival as well as coronary plaque samples obtained from patients diagnosed with chronic periodontitis with and without coronary artery disease. seventy-five participants were selected and grouped into 3 categories; 25 patients diagnosed with chronic periodontitis and coronary artery disease: cp + cad group; 25 patients diagnosed with chronic periodontitis alone: cp group; and 25 systemically and periodontally healthy controls (hp). demographic variables, periodontal parameters, cardiac parameters, blood pressure were obtained. mirna-146a and mirna126 levels were assessed in subgingival plaque (sp) samples from all the three groups. within cp+cad group, sp samples of cp+cada were compared with coronary plaques samples (cp) of cp+cadb while the patient underwent cabg.

Eligibility criteria:
inclusion criteria: * patients volunteering for the investigation. * patients between the age group of 30-70 years * presence of ≥ 15 natural teeth. exclusion criteria: * patients associated with systemic diseases such as lung disorders, renal disease, liver disease, type i, type ii-diabetes mellitus, hiv infection, rheumatoid arthritis, allergy or any malignancy. * under treatment with antibiotics, immunosuppressive drugs such as corticosteroids, within 6 months. * pregnant women and female patients were excluded because of the altered oral flora due to hormonal changes * smoking and other tobacco usage habits * patients who underwent periodontal treatment within 6 months.

Keywords: chronic periodontitis coronary artery disease microrna 146a microrna 126 plaque samples biomarkers
circulating tumor dna to monitor the efficacy of total neoadjuvant therapy for rectal cancer

Conditions: Colorectal Cancer; Rectal Cancer

Summary: the purpose of this study is to use the signateratm assay created from rectal tumor biopsies to monitor participants' blood for fragments of dna shed by tumor cells. the tumor dna fragments are referred to as circulating tumor dna, or ctdna for short.

rectal cancer tissue samples that were collected from participants' previous biopsies will be sent to natera for signatera assay creation after enrollment onto the study. one 6 ml tube of blood will be obtained at baseline prior to initiation of treatment. blood will also be obtained in two 6 tubes at the following points: 3-4 weeks into chemoradiation therapy (crt), after crt, after chemotherapy, after surgery for those who undergo resection, and during surveillance 3 months after surgery or at the end of treatment for one year after completion of tnt (total neoadjuvant therapy). the primary objective of the study is to estimate the percentage of patients with positive ctdna at the end of tnt . the secondary objectives of the study include: 1. estimating the change in ctdna after chemoradiation and chemotherapy 2. characterize the correlation of complete response to tnt with presence or absence of ctdna 3. describe the recurrence rate in participants with and without ctdna after tnt 4. characterize the correlation of ctdna at end of tnt with recurrence free survival at 2 years.

Eligibility criteria:
inclusion criteria: * newly histologically documented rectal adenocarcinoma or biopsy-proven adenoma with mri rectum and ct chest/abdomen or pet/ct imaging consistent with stage ii or iii disease * plan is for participant to undergo standard tnt with induction chemoradiation * age ≥ 18 years of age exclusion criteria: * stage i, recurrent, or metastatic rectal cancer * received prior therapy for this rectal cancer * no baseline tumor biopsies with adenocarcinoma or adequate amount of tissue from biopsies available to send for signateratm assay development

Keywords: total neoadjuvant treatment tumor-specific assay circulating tumor dna ctdna